These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3874038)

  • 21. Pharmacokinetics of graded oral doses of sulindac in man.
    Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
    Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Helicobacter pylori and gastric adaptation to repeated aspirin administration in humans.
    Konturek JW; Dembiński A; Konturek SJ; Domschke W
    J Physiol Pharmacol; 1997 Sep; 48(3):383-91. PubMed ID: 9376621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sulindac on in vitro immunologic function and on prostaglandin production by human peripheral blood mononuclear leukocytes.
    Nakamura T; Nagasaka T; Russell IJ
    Immunopharmacology; 1982 Dec; 5(2):157-67. PubMed ID: 6219075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.
    Piazza GA; Rahm AL; Krutzsch M; Sperl G; Paranka NS; Gross PH; Brendel K; Burt RW; Alberts DS; Pamukcu R
    Cancer Res; 1995 Jul; 55(14):3110-6. PubMed ID: 7606732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal prostaglandin E2 and F2 alpha synthesis during exercise: effects of indomethacin and sulindac.
    Zambraski EJ; Dodelson R; Guidotti SM; Harnett CA
    Med Sci Sports Exerc; 1986 Dec; 18(6):678-84. PubMed ID: 3537627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastric protection by nocloprost against aspirin damage in humans. Possible role of epidermal growth factor.
    Konturek SJ; Konturek JW; Kwiecien N; Obtułowicz W; Oleksy J; Hebzda Z; Amon I
    Scand J Gastroenterol; 1991 Mar; 26(3):231-6. PubMed ID: 1853145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
    Thompson HJ; Jiang C; Lu J; Mehta RG; Piazza GA; Paranka NS; Pamukcu R; Ahnen DJ
    Cancer Res; 1997 Jan; 57(2):267-71. PubMed ID: 9000566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ibuprofen lysinate and acetylsalicylic acid on gastric and duodenal mucosa. Randomized single-blind placebo-controlled endoscopic study in healthy volunteers.
    Müller P; Simon B
    Arzneimittelforschung; 1994 Jul; 44(7):840-3. PubMed ID: 7945519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine.
    Berkowitz JM; Adler SN; Sharp JT; Warner CW
    J Clin Gastroenterol; 1986 Jun; 8(3 Pt 2):377-80. PubMed ID: 3531311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine.
    Kimmey MB; Silverstein FE; Saunders DR; Chapman RC
    Dig Dis Sci; 1987 Aug; 32(8):851-6. PubMed ID: 3301232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulindac disposition when given once and twice daily.
    Swanson BN; Boppana VK; Vlasses PH; Holmes GI; Monsell K; Ferguson RK
    Clin Pharmacol Ther; 1982 Sep; 32(3):397-403. PubMed ID: 7049504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of acute aspirin-induced gastric mucosal injury by 15-R-15 methyl prostaglandin E2: an endoscopic study.
    Gilbert DA; Surawicz CM; Silverstein FE; Weinberg CR; Saunders DR; Feld AD; Sanford RL; Bergman D; Washington P
    Gastroenterology; 1984 Feb; 86(2):339-45. PubMed ID: 6360786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of indomethacin and sulindac on hydrochlorothiazide kinetics.
    Koopmans PP; Kateman WG; Tan Y; van Ginneken CA; Gribnau FW
    Clin Pharmacol Ther; 1985 Jun; 37(6):625-8. PubMed ID: 3891188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
    Duggan DE
    Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulindac. A potentially renal-sparing nonsteroidal anti-inflammatory drug.
    Bunning RD; Barth WF
    JAMA; 1982 Dec; 248(21):2864-7. PubMed ID: 7143649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation.
    Konturek JW; Dembinski A; Stoll R; Domschke W; Konturek SJ
    Gut; 1994 Sep; 35(9):1197-204. PubMed ID: 7959223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastric adaptation. Studies in humans during continuous aspirin administration.
    Graham DY; Smith JL; Spjut HJ; Torres E
    Gastroenterology; 1988 Aug; 95(2):327-33. PubMed ID: 3260568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological study of the effects of three anti-inflammatory preparations on the gastric mucosa.
    McIntyre RL; Irani MS; Piris J
    J Clin Pathol; 1981 Aug; 34(8):836-42. PubMed ID: 7276205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of gastric mucosal protection by sucralfate during long-term aspirin ingestion in humans.
    Stern AI; Ward F; Sievert W
    Am J Med; 1989 Jun; 86(6A):66-9. PubMed ID: 2660559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.